149 related articles for article (PubMed ID: 1739622)
1. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Peters GJ; Kraal I; Pinedo HM
Br J Cancer; 1992 Feb; 65(2):229-33. PubMed ID: 1739622
[TBL] [Abstract][Full Text] [Related]
2. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
3. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
4. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
Pizzorno G; Wiegand RA; Lentz SK; Handschumacher RE
Cancer Res; 1992 Apr; 52(7):1660-5. PubMed ID: 1551097
[TBL] [Abstract][Full Text] [Related]
5. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
6. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.
Peters GJ; van Dijk J; Laurensse E; van Groeningen CJ; Lankelma J; Leyva A; Nadal JC; Pinedo HM
Br J Cancer; 1988 Mar; 57(3):259-65. PubMed ID: 3355763
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
9. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
Schwartsmann G; Peters GJ; Laurensse E; de Waal FC; Loonen AH; Leyva A; Pinedo HM
Biochem Pharmacol; 1988 Sep; 37(17):3257-66. PubMed ID: 2840910
[TBL] [Abstract][Full Text] [Related]
10. The "anti-pyrimidine effect" of hypoxia and brequinar sodium (NSC 368390) is of consequence for tumor cell growth.
Löffler M
Biochem Pharmacol; 1992 May; 43(10):2281-7. PubMed ID: 1599514
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo mechanisms of action of the antiproliferative and immunosuppressive agent, brequinar sodium.
Xu X; Williams JW; Shen J; Gong H; Yin DP; Blinder L; Elder RT; Sankary H; Finnegan A; Chong AS
J Immunol; 1998 Jan; 160(2):846-53. PubMed ID: 9551920
[TBL] [Abstract][Full Text] [Related]
12. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.
Nadal JC; van Groeningen CJ; Pinedo HM; Peters GJ
Invest New Drugs; 1989 Jul; 7(2-3):163-72. PubMed ID: 2793368
[TBL] [Abstract][Full Text] [Related]
14. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
15. Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.
Chen TL; Erlichman C
Cancer Chemother Pharmacol; 1992; 30(5):370-6. PubMed ID: 1380407
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
Chen SF; Ruben RL; Dexter DL
Cancer Res; 1986 Oct; 46(10):5014-9. PubMed ID: 3019518
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine.
Thomson TA; Spinella-Jaegle S; Francesconi E; Meakin C; Millet S; Flao KL; Hidden H; Ruuth E
Scand J Immunol; 2002 Jul; 56(1):35-42. PubMed ID: 12100469
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]